Among the patients analyzed, we hypothesized that harboring low-level WT1 expression may be a hallmark of complex disease, with mutations in key myeloid tumor suppressor genes accumulating over time, signifying a significant correlation between low WT1 expression and adverse genomic profiles. Here, WT1 is linked to neoplasm.